

1 Title. Effects of short-term energy restriction on liver lipid content and inflammatory status in
2 severely obese adults: results of a randomised controlled trial (RCT) using two dietary
3 approaches.

4 Authors:

5 Emma L Baldry¹

6 Guruprasad P. Aithal²

7 Philip Kaye³

8 Iskandar R Idris⁴

9 Andrew Bennett⁶

10 Paul C Leeder⁵

11 Ian A Macdonald⁶

12 ¹ Faculty of Medicine & Health Sciences, University of Nottingham, University of Nottingham
13 Medical School, Queen's Medical Centre, Nottingham, NG7 2UH

14 ² National Institute for Health Research (NIHR) Nottingham Digestive Diseases Biomedical
15 Research Unit (BRU), Nottingham University Hospitals NHS Trust and University of
16 Nottingham, University of Nottingham Medical School, Queen's Medical Centre, Nottingham,
17 NG7 2UH

18 ³ Department of Cellular Pathology, Nottingham University Hospitals NHS Trust, Nottingham
19 Digestive Diseases Centre BRU, University of Nottingham, Queens Medical Centre,
20 Nottingham, NG7 2UH

21 ⁴ MRC Musculoskeletal Physiology and Ageing, Division of Medical Sciences & Graduate Entry
22 Medicine, Derby Teaching Hospital, University of Nottingham, DE22 3DT

23 ⁵ The East-Midlands Bariatric & Metabolic Institute (EMBMI), Derby Teaching Hospitals NHS
24 Foundation Trust, Royal Derby Hospital, Uttoxeter Road, Derby, DE22 3NE

25 ⁶ Faculty of Medicine & Health Sciences, University of Nottingham, University of Nottingham
26 Medical School, Queen's Medical Centre, Nottingham, NG7 2UH

27 Short title. Effects of two short-term pre-bariatric surgery diets.

28 Abstract word count:189

29 Main text word count:1776

30 Number of references: 15

31 Number of tables:2

32 Supplementary data

33 Address for correspondence:

34 Emma Baldry

35 Leicester Diabetes Centre, Leicester General Hospital, Gwendolen Road, Leicester LE5 4PW

36 E mail: emma.baldry@uhl-tr.nhs.uk

37

38 **Abstract**

39 Short-term very low energy diets (VLED) are used in clinical practice prior to bariatric surgery,
40 however, regimens vary and outcomes for a short intervention are unclear. We examined the effect
41 of two VLEDs; a food-based diet (FD) and meal replacement plan (MRP) (LighterLife) over two weeks
42 in a randomised controlled trial (RCT). We collected clinical and anthropometric data, fasting blood
43 samples, and dietary evaluation questionnaires. Surgeons took liver biopsies and made a visual
44 assessment of the liver. We enrolled 60 participants and 54 completed (FD n=26, MRP n=28).
45 Baseline demographic features, reported energy intake, dietary evaluation and liver histology were
46 comparable between groups. Both diets induced significant weight loss. Perceived difficulty of
47 surgery correlated significantly with the degree of steatosis on histology. Circulating inflammatory
48 mediators: CRP, Fetuin-A and IL6 reduced pre to post diet. Diets achieved comparable weight loss
49 and reduction in inflammatory biomarkers, perceived operative difficulty, and patient evaluation.
50 NAFLD histology assessments post-diet were also not significantly different between diets. Results
51 indicate effectiveness of short term very low energy diets and energy restriction irrespective of
52 macronutrient composition although small sample size precluded detection of subtle differences
53 between interventions.

54 **Keywords**

55 VLED, preoperative, bariatric, NAFLD, energy restriction

56 **Introduction**

57 Ectopic lipid accumulation is a common factor underlying non-alcoholic fatty liver disease (NAFLD),
58 insulin resistance and Type 2 diabetes (DM) (1). Metabolic dysfunction is linked to pro-
59 inflammatory mediators such as Interleukin-6 (IL6), Fetuin-A and C-reactive protein (CRP), which also
60 contribute to progression to inflammatory non-alcoholic steatohepatitis (2-4).

61 An energy restricted diet is used prior to bariatric surgery to facilitate the laparoscopic approach to
62 surgery via a reduction in liver size and improved liver flexibility, by reducing stores of lipid, enabling
63 access to the upper stomach and oesophagus (5). In practice, this is achieved with the use of a
64 short-term pre-operative very low energy diet (VLED), or “liver reducing” diet. Our survey of current
65 practice in 2013 found significant variability in form, duration and application of the pre-operative
66 diet used (6).

67 Although weight loss via a VLED is associated with reversal of the obesity related complications due
68 to the reduction of ectopic lipid deposits (7), there is limited evidence for the effects of the different
69 pre-surgery VLEDs on outcomes related to liver histology, inflammatory markers and their
70 effectiveness related to perceived operative difficulty.

71 We therefore examined the outcomes of two commonly used VLED regimens in severely obese
72 adults prior to undergoing bariatric surgery. Our primary outcome was liver histology post-diet, with
73 secondary outcomes including weight loss achieved, circulating inflammatory markers pre to post
74 diet, and peri-operative visual assessment of the liver for perceived difficulty of surgery. We also
75 asked participants to evaluate the diets.

76 **Materials and Methods**

77 **Study design**

78 The study was registered <http://www.isrctn.com/>, registration number: ISRCTN65605485.

79 We conducted the RCT between May 2012 and June 2014. Patients were eligible if they had a body
80 mass index (BMI) $>40\text{kgm}^2$ and acceptance onto the bariatric surgical programme at Derby Hospitals
81 NHS Foundation Trust following discussion at the bariatric MDT. Participant exclusion criteria

82 included; age <18years, secondary NAFLD, Type 2 diabetes treated by medication other than
83 Biguanides, excess alcohol intake, pregnancy, and exclusions linked to application of a restrictive
84 dietary regime.

85 Participants were randomly allocated to receive 800kcal/d VLED for two weeks pre-operatively,
86 either Derby Teaching Hospitals NHS Foundation Trust standard pre-bariatric surgery food-based
87 diet (FD) or a Meal replacement plan diet using LighterLife nutritional supplements (MRP). Block
88 randomisation was used with matched pairs, for gender and diabetes status. The participants, and
89 study team who supplied the dietary information to participants, were not blinded to intervention.

90 **Sampling and data collection**

91 Clinical and anthropometric data were collected during visits and from patients' notes. A pre-
92 intervention fasting blood test, weight and height, were taken at the time of the standard pre-
93 operative appointment. On completion of the diet participants completed a short qualitative
94 evaluation. Participants were weighed post-diet on the morning of their bariatric surgery. When the
95 participant was cannulated for anaesthesia a further fasting blood sample was taken. Intra-
96 operatively a liver biopsy was taken and the surgeon completed a visual assessment of perceived
97 operative difficulty.

98 **Outcome measures**

99 Primary outcome was histological assessment of a liver biopsy performed at the time of bariatric
100 surgery (post-diet), secondary outcomes were change in total body weight (pre to post diet),
101 circulating inflammatory markers (pre to post-diet), peri-operative visual assessment of the liver for
102 perceived difficulty of surgery and evaluation of dietary approach (post-diet).

103 **Sample size**

104 The sample size was based on an estimation of the difference in liver lipid after following FD or MRP.
105 For 80% power (at $p=0.05$) 98 participants would need to be randomised (49 to each arm) to see a
106 statistically significant difference in the level of steatosis (InStat Graph Pad V2.0 software).

107 **Statistical methods**

108 The data were analysed with IBM SPSS Statistics for WINDOWS version 22 (IBM Corporation). Two-
109 tailed non-parametric statistical tests were used; Wilcoxon signed rank test, Spearman's Rho, Mann-
110 Whitney U test, and Kendall's Tau C Test. Threshold of significance was defined at $P < 0.05$.
111 Bonferroni correction for multiple comparisons was carried out where stated.
112 Further details of methods and data collection are in Supplementary data.

113 **Results**

114 196 potential participants were screened for eligibility over a 25 months period of recruitment. 105
115 verbally consented to the study, 60 completed informed consent, were randomised and started the
116 trial, and 54 completed. Six participants did not complete the study; five due to operations being
117 cancelled and one patient was started on insulin. One adverse event, and one serious adverse
118 event, were reported but were not deemed to be related to the intervention.

119 **Baseline data** (Table 1)

120 Participants' BMI ranged from 41.5-66.8kg/m², with a median of 50.7kg/m². 81.5% of participants
121 were female, which is consistent with the national average for patients undergoing bariatric surgery.
122 Age ranged from 24 to 65 years, with median 45. There was no significant difference between diet
123 groups demographically or anthropometrically (age $P=0.245$, BMI $P=0.691$, gender $P=0.568$, DM
124 status $P=0.860$).

125 **Liver tissue histology** (Table 2)

126 Following the intervention, 12 of 24 participants in the FD group (50%), and 18 of 28 participants in
127 the MRP group (64%) had histological evidence of steatosis, which were not significantly different.
128 Three of 24 participants in the FD group (12.5%) and four of 28 participants in the MRP group
129 (14.3%) showed evidence of moderate or severe steatosis (steatosis grade 2-3). 37% of participants
130 in the FD group, and 39% of participants in the MRP group, showed evidence of significant portal or
131 periportal fibrosis; but the difference between groups was not statistically significant. No significant
132 difference was found between diet groups for steatosis grade ($P=0.349$), liver cell injury ($P=0.567$),
133 portal inflammation ($P=0.611$), lobular inflammation ($P=0.455$), or fibrosis stage ($P=0.605$).

134 **Weight change and self-reported intake** (Table 1)

135 Median total body weight loss was 3.6% in the FD group, and 3.4% in the MRP group. Results were
136 not significantly different between diet groups, for body weight loss or percentage weight loss
137 (P=0.494 and P=0.993 respectively).

138 Median energy intakes (kcal/d) were not statistically different between diet groups (P=0.311).

139 Macronutrient energy intake (% total energy intake) differed between the two diets, with protein,
140 fat and carbohydrate intakes being significantly different between groups (P<0.001 Mann-Whitney
141 U-Test Bonferroni correction α error probability threshold 0.016). Fluid intake recommendations
142 were a minimum of 2L/d, with median reported intakes of 2.2L/d FD, and 2.5L/d MRP.

143 **Surgeons' assessment**

144 In 22 of the 54 cases, a surgeon completed a visual assessment of 1) access to the gastro-
145 oesophageal junction, 2) liver volume and 3) liver rigidity. Increasing perceived difficulty was
146 associated with higher percentages of steatosis (as assessed histologically). There was a correlation
147 between visual assessment by the surgeons and the three assessment categories (above). There
148 was no significant difference between diets for the three visual analogue assessments; gastric access
149 (P=0.513), liver volume (P=0.891), liver rigidity (P=0.702).

150 **Blood results**

151 Concentrations of CRP and Fetuin-A reduced significantly after both diets. IL6 reduction was not
152 significant.

153 **Dietary evaluation**

154 Participants' self-reported evaluation showed overall satisfaction with the diets was 92% and 85%
155 satisfied or very satisfied. 82% in the FD group and 93% on the MRP reported that they found the
156 diet easy to follow. 19% in the FD and 15% in the MRP reported always feeling hunger, whereas 8%
157 and 11% respectively never felt hungry. There were no significant differences between evaluation
158 responses for satisfaction, ease of use or hunger frequency between diets.

159 Further results in Supplementary data.

160 **Discussion**

161 This RCT examined two energy restrictive dietary regimens aiming for 800kcal/d for a period of two
162 weeks prior to bariatric surgery. We found that both dietary approaches achieved equivalent and
163 significant outcomes. In the two week period of intervention, patients in both groups lost about
164 3.5% of their total body weight, alongside a reduction in CRP, and Fetuin-A . This reflects an
165 improvement in obesity related systemic inflammation which requires further work to evaluate
166 clinical significance.

167 Macronutrient composition between FD and MRP were significantly different with 52% of total
168 energy intake from carbohydrate in the FD compared to 38% in MRP group. A previous study has
169 demonstrated that a reduced carbohydrate diet with moderate energy restriction leads to
170 significantly more reduction in liver lipid at 48hours than a higher-carbohydrate diet (8). Our results
171 demonstrate that when VLED interventions are considered over a period of two weeks, both FD and
172 MRP were effective irrespective of macronutrient composition.

173 The main objective of a pre-operative energy restrictive dietary intervention is to improve intra-
174 operative conditions for a laparoscopic surgical procedure. At the time of surgery, we found a lower
175 than expected proportion of patients had histological evidence of NAFLD on liver biopsy (9) and
176 steatosis levels were associated with visual assessment by the surgeons of operative difficulty. Both
177 of the pre-operative diets could therefore be reasoned to have enabled surgery, from the
178 perspective of reducing difficulty of the surgery, due to limiting steatosis.

179 We also observed reduction in the biomarkers of obesity related systemic inflammatory response.

180 Fetuin-A is an endogenous ligand for Toll-like receptor-4 through which free fatty acids induce
181 inflammatory signalling and insulin resistance (10). Patients with severe obesity have markedly
182 raised Fetuin-A levels. Markers of systemic inflammation, such as CRP, have been found to be
183 determinants of risk for development of DM (11). Although our findings in the RCT are in line with
184 observations elsewhere, where these markers correlate with measures of obesity, and reduce with
185 significant weight loss (12-14), the majority of these observations were after longer periods of

186 energy restriction and greater weight loss. The novelty of our findings were that the observed
187 reduction in pro-inflammatory cytokines occurred after only two weeks and 3.5% weight loss.
188 The main limitation to this work is the failure to reach the sample size. However, the results for
189 NAFLD are similar to observations elsewhere after an energy restrictive diet when applied in the
190 severely obese population (15). Further, we were unable to obtain liver biopsies or perform non-
191 invasive estimation of hepatic lipid content using MRI both prior to and after the interventions,
192 which would have allowed for more conclusive outcome appraisal. Randomisation however appears
193 to have been effective and no significant differences in demographic or anthropometric profile were
194 observed between the two groups at baseline.

195

196 **In conclusion**, our results indicate that energy intake of 715kcal/d for two weeks improves operative
197 conditions regardless of the macronutrient composition. Patients were satisfied with VLEDs, which
198 they also found easy to use. The fatty liver disease we found was in line with similar studies and is
199 suggestive of an effect of both diets in reducing liver lipid. Reductions in inflammatory biomarkers
200 require further investigation. We were unable to demonstrate a difference in either case between
201 diets, and small sample size may have precluded detection of subtle differences.

202

203 **Statement of authorship:**

204 Guruprasad P Aithal, Andrew Bennett and Ian Macdonald all contributed to the conception and
205 design of the study. Ian Macdonald, Paul Leeder and Iskandar Idris supported the organisation of
206 the study and acquisition of data/samples. Philip Kaye completed histological assessment of liver
207 biopsies. Emma Baldry collected, processed and analysed all data/samples. All authors contributed
208 to interpretation of data and the drafting of the article.

209 **Acknowledgements:**

210 Thanks to LigherLife for providing the meal replacement products used in the study free of charge.

211

212 References

- 213 1. Virtue S, Vidal-Puig A. Adipose tissue expandability, lipotoxicity and the Metabolic
214 Syndrome — An allostatic perspective. *Biochimica et Biophysica Acta (BBA) - Molecular and*
215 *Cell Biology of Lipids*. 2010;1801(3):338-49.
- 216 2. Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE. Increased
217 Hepatic and Circulating Interleukin-6 Levels in Human Nonalcoholic Steatohepatitis. *Am J*
218 *Gastroenterol*. 2008;103(6):1372-9.
- 219 3. Yoneda M, Mawatari H, Fujita K, Iida H, Yonemitsu K, Kato S, et al. High-sensitivity C-
220 reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and
221 also of the severity of fibrosis in NASH. *Journal of Gastroenterology*. 2007 2007//;42(7):573-82.
- 222 4. Trepanowski JF, Mey J, Varady KA. Fetuin-A: a novel link between obesity and related
223 complications. *Int J Obes*. [Review]. 2015.
- 224 5. Colles SL, Dixon JB, Marks P, Strauss BJ, O'Brien PE. Preoperative weight loss with a
225 very-low-energy diet: quantitation of changes in liver and abdominal fat by serial imaging. *The*
226 *American Journal of Clinical Nutrition*. 2006 August 1, 2006;84(2):304-11.
- 227 6. Baldry E, Leeder P, Idris I. Pre-operative Dietary Restriction for Patients Undergoing
228 Bariatric Surgery in the UK: Observational Study of Current Practice and Dietary Effects. *Obes*
229 *Surg*. 2014 2014/03/01;24(3):416-21.
- 230 7. Steven S, Taylor R. Restoring normoglycaemia by use of a very low calorie diet in long-
231 and short-duration Type 2 diabetes. *Diabetic medicine : a journal of the British Diabetic*
232 *Association*. 2015 Feb 12.
- 233 8. Kirk E, Reeds DN, Finck BN, Mayurranjan MS, Patterson BW, Klein S. Dietary Fat and
234 Carbohydrates Differentially Alter Insulin Sensitivity During Caloric Restriction. *Gastroenterology*.
235 2009;136(5):1552-60.
- 236 9. Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients
237 undergoing bariatric surgery. *Journal of Hepatology*. 2006 Oct;45(4):600-6.
- 238 10. Pal D, Dasgupta S, Kundu R, Maitra S, Das G, Mukhopadhyay S, et al. Fetuin-A acts as
239 an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. *Nat Med*. [Research
240 Support, Non-U.S. Gov't]. 2012 Aug;18(8):1279-85.
- 241 11. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6,
242 and risk of developing type 2 diabetes mellitus. *JAMA*. 2001;286(3):327-34.
- 243 12. Brix JM, Stingl H, Höllerl F, Schernthaner GH, Kopp H-P, Schernthaner G. Elevated
244 Fetuin-A Concentrations in Morbid Obesity Decrease after Dramatic Weight Loss. *J Clin Endocr*
245 *Metab*. 2010 November 1, 2010;95(11):4877-81.
- 246 13. Bastard J-P, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M, et al. Elevated Levels of
247 Interleukin 6 Are Reduced in Serum and Subcutaneous Adipose Tissue of Obese Women after
248 Weight Loss. *The Journal of Clinical Endocrinology & Metabolism*. 2000;85(9):3338-42.
- 249 14. Moschen AR, Molnar C, Geiger S, Graziadei I, Ebenbichler CF, Weiss H, et al. Anti-
250 inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and
251 tumour necrosis factor α expression. *Gut*. 2010 September 1, 2010;59(9):1259-64.
- 252 15. Lewis M, Phillips M, Slavotinek J, Kow L, Thompson C, Toouli J. Change in liver size and
253 fat content after treatment with Optifast (R) very low calorie diet. *Obes Surg*. 2006 JUN
254 2006;16(6):697-701.

255 Tables

256

257 Table 1 Baseline data; Body mass index (BMI), gender, age and diabetes status for the 54
258 participants that completed the study, separated by dietary intervention. There were no statistically
259 different results between diet groups.

260 Post-diet results for body weight loss (%), self-reported energy intake (kcal/d), and macronutrient
261 composition of energy intake (kcal/d). There was no statistically significant difference between
262 weight loss (P=0.993) or estimated energy intake (P=0.311), however all macronutrient intakes were
263 significantly different (P<0.001).

264 All data shown as median (range) unless stated otherwise.

265

| | FD (n=26) | MRP (n=28) | |
|--|---------------------|-------------------|-----------|
| Gender: female/ male (n) | 22/4 | 22/6 | |
| No. with Type 2 Diabetes (%) | 8 (31) | 8 (29) | |
| Age in years | 47 (40) | 42 (35) | |
| BMI kg/m² | 51.1 (25.4) | 50.1 (21.4) | |
| Post-diet results | | | |
| Weight Loss % | 3.6 (3.0) | 3.4 (3.7) | |
| Estimated energy intake kcal/d | 715 (558) | 715 (275) | |
| Macronutrient % total energy intake | Carbohydrate | 52 (21.5) | 38 (7.8) |
| | Protein | 30 (14.7) | 37 (7.2) |
| | Fat | 19 (18.8) | 25 (14.3) |

266

267 Table 2
 268 Liver histology results from time of surgery (post-diet).
 269 Steatosis results for grade and location, liver cell injury results including lobular and portal
 270 inflammation and fibrosis stage (CRN) for both dietary approaches.
 271 Shown as count (n).
 272

| | | FD (n=24)* | MRP (n=28) |
|--|---|-----------------------|-----------------------|
| Steatosis grade 0-3 | 0 | 12 | 10 |
| | 1 | 9 | 14 |
| | 2 | 2 | 2 |
| | 3 | 1 | 2 |
| Steatosis location 0-3 | 0 | 22 | 27 |
| | 1 | 0 | 0 |
| | 2 | 2 | 1 |
| | 3 | 0 | 0 |
| Liver cell injury (ballooning/ apoptosis) 0-3 | 0 | 18 | 19 |
| | 1 | 6 | 9 |
| | 2 | 0 | 0 |
| Lobular inflammation 0-3 | 0 | 12 | 19 |
| | 1 | 10 | 5 |
| | 2 | 0 | 2 |
| | 3 | 1 | 2 |
| Portal inflammation 0-3 | 0 | 4 | 2 |
| | 1 | 11 | 15 |
| | 2 | 9 | 11 |
| Fibrosis Stage (detailed CRN definitions) | None | 8 | 6 |
| | Mild zone 3 perisinusoidal (1a) | 0 | 2 |
| | Portal/periportal (1c) | 12 | 14 |
| | Perisinusoidal and portal/periportal (2) | 2 | 6 |
| | Bridging fibrosis (3) | 0 | 0 |
| | Cirrhosis (4) | 2 | 0 |

273
 274 * Two participants in the FD group were unable to have liver biopsies taken at the time of surgery.